Results 71 to 80 of about 491,602 (238)

Understanding Further the Phenotypic Spectrum of Central Nervous System Inflammatory Demyelinating Disorders Using Unsupervised Clustering

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Central nervous system (CNS) inflammatory demyelinating syndromes, including multiple sclerosis (MS), aquaporin‐4 antibody–positive neuromyelitis optica spectrum disorder (AQP4 + NMOSD), and myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD), occasionally overlap.
Bade Gulec, Elif Everest, Melih Tutuncu, Ugur Bilge, Sabahattin Saip, Ugur Uygunoglu, Aksel Siva   +6 more
wiley   +1 more source

Efecto del antitumoral verteporfina sobre la respuesta inmune mediada por interferón en células de pez [PDF]

, 2022
Existen evidencias de una interconexión entre el desarrollo del cáncer y el sistema inmunológico. Hemos investigado en este trabajo está posible conexión usando el modelo VTPF-SVCV-EPC. El antitumoral VTPF es un inhibidor de la vía Hippo-YAP, una ruta
Gómez Quintanilla, Ainhoa
core  

Influenza Vaccination Responses in Disabled Stroke Patients: A Single‐Center Prospective Observational Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aimed to investigate the immunological response to influenza vaccination, the incidence and severity of influenza infection, and the side effects of the vaccination in patients with ischemic stroke. Methods This prospective observational study was conducted between 2023 and 2024 at Ramathibodi Hospital.
Achiraya Pakngao, Sureerat Suwatcharangoon, Pintip Ngamjanyapron, Kobporn Boonnak, Thanitta Suangtamai, Porpon Rotjanapan   +5 more
wiley   +1 more source

Sarcoidosis tras tratamiento con interferón y ribavirina. Presentación de un caso y revisión de la bibliografía

, 2004
El tratamiento con interferón alfa en la hepatitis crónica activa por el virus C tiene una eficacia demostrada, por ello se está generalizando su uso a gran número de pacientes. Entre los efectos secundarios, las manifestaciones respiratorias banales son
Pérez Ronchel, José, Merino Sánchez, Mercedes, Alfageme Michavila, Inmaculada, López Garrido, Juan, Lara Lara, Isabel, Suárez García, Eugenio   +5 more
core  

Estudio del interferón tipo III sobre la infección del virus del dengue [PDF]

, 2016
"En las enfermedades virales, la infección es controlada en la célula por el interferón tipo I (IFN-α), sin embargo, el virus del dengue (DENV) tiene la capacidad de inhibir esta respuesta. El interferón tipo III, también conocido como interferón lambda (
Palma Ocampo, Helen Kenia, PALMA OCAMPO, HELEN KENIA; 227637   +1 more
core  

Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels are believed to reflect mainly acute and chronic disease processes in multiple sclerosis (MS), respectively. In this study, we investigated whether dimethyl fumarate (DMF) and rituximab (RTX) differentially affect these biomarkers.
F. Shawket, J. Lycke, J. Salzer, F. Piehl, K. Fink, N. Lange, J. Mellergård, C. Malmeström, P. Sundström, I. Erngren, A. al‐Grety, E. Freyhult, K. Kultima, J. Burman, A. Svenningsson   +14 more
wiley   +1 more source

Dictamen Preliminar de Evaluación de Tecnología Sanitaria N° 007-DETS-IETSI-2021. Eficacia y seguridad de fingolimod en pacientes adultos con esclerosis múltiple recurrente remitente con falla al tratamiento con interferón beta [PDF]

, 2021
En este documento se plasma la evaluación de la eficacia y seguridad del uso del producto farmacéutico fingolimod en pacientes adultos con esclerosis múltiple recurrente remitente con falla al tratamiento con interferón beta; cuyos resultados sustentaron
Seguro Social de Salud (EsSalud). Instituto de Evaluación de Tecnologías en Salud e Investigación (IETSI). Dirección de Evaluación de Tecnologías Sanitarias, Ayala Quintanilla, Beatriz Paulina, Zavala Loayza, José Alfredo, Bendezu Quispe, Guido Jean Pierre, Peralta Aguilar, Verónica Victoria   +4 more
core  

Movement Disorders in Aicardi–Goutières Syndrome and Response to Immunomodulation

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT This study characterizes movement disorders and treatment responses in seven children with Aicardi–Goutières syndrome (AGS). We retrospectively evaluated motor phenotypes, neuroimaging, and interferon signatures in patients treated with baricitinib or anifrolumab. Spasticity affected all patients, while dystonia was present in 4/7.
Enrique Gonzalez Saez‐Diez, Monica Ferrer Socorro, Kathryn Yang, Nicole Battaglia, Zainab Zaman, Mariko Bennett, Adeline Vanderver, Pui Y. Lee, Lauren A. Henderson, Milena M. Andzelm, Darius Ebrahimi‐Fakhari   +10 more
wiley   +1 more source

Upper Cervical Cord Area as a Biomarker of Conversion to Secondary Progressive Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study assessed whether upper cervical cord area (UCCA) measured on routine brain MRI can serve as a biomarker of conversion to SPMS. Methods This is a single‐center retrospective cohort study of RRMS patients with cross‐sectional and longitudinal analyses of clinical and MRI data. Future SPMS converters were matched by age, sex,
Nabil K. El Ayoubi, Sola Al Ghazal, Salem Hannoun, Medhat A. Siddik, Nour M. Najjar, Jim Dagher, Joseph Abboud, Myriam G. Semaan, Samia J. Khoury   +8 more
wiley   +1 more source

Intensive Farmaco- Surveillance of Interferon Alpha 2b Recombinant in Multiple Sclerosis.

Medisur, 2007
Background: The interferon alpha 2b recombinant, produced in Cuba, is used in the treatment of different illnesses, such as the multiple sclerosis. For its commercialization it is needed to know its safety scope.
Leslie Pérez Ruiz, Ana María Ramos Cedeño, José Cabrera Gómez, Nancy Echazábal Santana, Hailen Bobillo López   +4 more
doaj   +2 more sources